Melinta Therapeutics Lands $67,000,000 New Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=fafd2a6c-506a-4750-8fa7-2fad2ad5659c - Date
6/10/2015 - Company Name
Melinta Therapeutics - Mailing Address
300 George Street New Haven, CT 06511 USA - Company Description
Melinta Therapeutics’ mission is to discover, develop and commercialize groundbreaking antibiotics to overcome drug-resistant, life-threatening infections. - Website
http://www.melinta.com - Transaction Type
Venture Equity - Transaction Amount
$67,000,000 - Transaction Round
Undisclosed - Proceeds Purposes
Proceeds from the financing will be used to complete the final Phase 3 study of delafloxacin, an investigational fluoroquinolone, currently undergoing a confirmatory Phase 3 study for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI). Funds will also support the potential submission of a New Drug Application (NDA) for delafloxacin for the lead indication, pursuing new indications for delafloxacin including hospital-treated community-acquired bacterial pneumonia (hCABP), and advancing a lead candidate for the company’s ESKAPE pathogen program. - M&A Terms
- Venture Investor
- Venture Investor
- Venture Investor
